How to Get Vyleesi in Alaska: Telehealth, Prescriptions, and Pharmacies

What Is Bremelanotide and Why Does It Require a Prescription?

Bremelanotide is a melanocortin receptor agonist that acts on MC3R and MC4R receptors in the central nervous system to increase sexual desire. The FDA approved it on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women who do not have a co-existing sexual dysfunction disorder. It is a Schedule V-equivalent prescription drug with a boxed warning related to transient blood-pressure changes, which is why prescriber involvement is not optional.

The key RECONNECT trials (two randomized, double-blind, placebo-controlled studies; N=1,267 combined) demonstrated that women using bremelanotide reported statistically significant improvements in satisfying sexual events and Female Sexual Function Index desire scores compared with placebo, with a mean increase of 0.5 on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) versus 0.3 for placebo (P<0.001) 1. The FDA label notes that approximately 40% of bremelanotide-treated women experienced nausea, the most common adverse effect, and that the drug transiently raises mean systolic blood pressure by approximately 2 mmHg and diastolic by approximately 1 mmHg within 12 hours of injection 2.

Because of those cardiovascular signals, prescribers are required to document a baseline blood-pressure reading and review any history of cardiovascular disease before writing the first prescription. That clinical step happens seamlessly within an Alaska telehealth visit.

Is Telehealth Prescribing of Vyleesi Legal in Alaska?

Yes. Alaska statute permits synchronous and asynchronous telehealth prescribing by licensed physicians, nurse practitioners, and physician assistants. The Alaska Telehealth Advisory Committee has confirmed that an audio-video visit establishes a valid patient-provider relationship sufficient for a new prescription under Alaska Stat. § 08.64.364 3. No separate in-person physical examination is required for HSDD medications as long as the provider meets their professional standard of care.

This regulatory posture matters for geography. Alaska has roughly 737,000 residents spread across 663,000 square miles. For women in Fairbanks, Juneau, Sitka, Nome, or the Kenai Peninsula, driving to a gynecologist or sexual health specialist is not always realistic. A telehealth visit removes that barrier entirely.

The Drug Enforcement Administration's telehealth prescribing rules (which restrict controlled substances via video) do not apply to bremelanotide. Bremelanotide is not a DEA-scheduled controlled substance 4. An Alaska prescriber can write the order after a single compliant telehealth encounter.

Who Can Prescribe Vyleesi in Alaska?

Any Alaska-licensed MD, DO, NP, or PA with prescriptive authority can prescribe bremelanotide, provided the clinician completes a HSDD-appropriate assessment. Scope-of-practice law in Alaska grants certified nurse practitioners full independent prescriptive authority under Alaska Stat. § 08.68.100 5, meaning an NP-run telehealth service carries exactly the same legal weight as a physician consult for this indication.

Most HealthRX patients are seen by either a board-certified OB-GYN or a family-medicine physician with specific experience in women's sexual health. The clinician documents all of the following before transmitting the prescription:

• A confirmed HSDD diagnosis using DSM-5 criteria (distressing low desire not explained by another condition or relationship factor) 6
• Blood pressure recorded during or immediately before the visit
• Absence of uncontrolled hypertension (resting BP consistently above 130/80 mmHg is a relative contraindication per the FDA label)
• Review of concurrent medications, particularly those that raise blood pressure or interact with melanocortin pathways
• Patient-reported menstrual status confirming premenopausal state

What Labs Are Required Before a Vyleesi Prescription in Alaska?

Baseline labs are not mandated by the FDA label, but most responsible prescribers order a small panel to rule out secondary causes of low desire and to document cardiovascular safety. Expect the following:

Comprehensive metabolic panel (CMP). Rules out hepatic dysfunction and electrolyte imbalances that could complicate melanocortin signaling. Reference ranges and clinical interpretation follow AACE endocrine testing guidelines 7.

Fasting lipid panel. Documents baseline cardiovascular risk given the transient blood-pressure effect of bremelanotide. The American Heart Association recommends lipid screening every 4-6 years in women without risk factors, more frequently with risk factors present 8.

Thyroid-stimulating hormone (TSH). Hypothyroidism is a common, correctable cause of low libido. The American Thyroid Association notes that TSH above 4.5 mIU/L in a symptomatic woman warrants treatment before attributing desire changes to primary HSDD 9.

Pregnancy test (urine or serum beta-hCG). Bremelanotide is contraindicated in pregnancy. The FDA pregnancy category data show embryo-fetal toxicity in animal studies at doses above the human equivalent 2.

Blood pressure must be documented on the day of the visit. Home blood-pressure cuffs are widely available, and most Alaska telehealth platforms accept patient-submitted readings with photo or video verification.

Alaska residents can use any national CLIA-certified lab. Quest Diagnostics serves Anchorage, Fairbanks, and Juneau. LabCorp has a patient service center in Anchorage. For patients in remote areas, mobile phlebotomy services and at-home blood-draw kits exist; the prescriber can coordinate the order electronically.

How to Get a Vyleesi Prescription Through Telehealth in Alaska: Step by Step

The process has four stages. Each takes a defined amount of time, so you can plan around them.

Stage 1: Intake form (10-15 minutes). The patient completes a structured intake questionnaire that mirrors DSM-5 HSDD criteria and captures medication history, cardiovascular history, and menstrual status. HealthRX uses validated instruments including the Female Sexual Function Index (FSFI), a 19-item self-report tool with an established threshold score of 26.55 below which sexual dysfunction is indicated 10.

Stage 2: Lab draw (1-5 business days depending on location). Labs are ordered at intake. Results upload automatically for most national labs via HL7 interfaces. Remote Alaska patients may need an extra 2-3 days for mobile or mailed-kit results.

Stage 3: Telehealth visit (20-30 minutes). The prescriber reviews lab results, records blood pressure, confirms diagnosis, and addresses any contraindications. The visit is conducted over HIPAA-compliant video. Patients in areas without broadband may use audio-only under Alaska's telehealth statute.

Stage 4: Prescription transmission and pharmacy fulfillment (2-10 business days). The e-prescription goes to the patient's preferred pharmacy. Standard retail pharmacies in Anchorage stock Vyleesi; rural patients typically receive shipment via mail-order or 503A compounding pharmacy. Total elapsed time from initial intake to drug-in-hand: 5-14 business days for most Alaska ZIP codes.

Pharmacy Options for Bremelanotide in Alaska

Three pathways exist for filling a bremelanotide prescription in Alaska.

Brand Vyleesi at a retail pharmacy. Walgreens and Caremark-affiliated pharmacies in Anchorage stock or can special-order the brand autoinjector. The list price is approximately $990 per carton (4 autoinjectors). Palatin Technologies operates a patient savings program that may reduce out-of-pocket cost to as low as $99 per month for commercially insured patients who meet income criteria 11. Patients should call the pharmacy 48-72 hours ahead to confirm stock because Alaska supply chains can experience delays.

Mail-order through a national specialty pharmacy. Specialty pharmacies such as Optum Specialty Pharmacy and Walgreens Specialty Pharmacy ship temperature-controlled packages to Alaska addresses, including many remote communities reachable by USPS. Shipping typically adds 2-4 business days.

503A compounding pharmacies. A 503A pharmacy compounds drug products for individual patients based on a valid prescription. Alaska law permits 503A pharmacies licensed in the state to fill and ship compounded bremelanotide 12. Compounded versions are typically provided as a lyophilized powder for reconstitution or a pre-mixed subcutaneous solution. They are not FDA-approved finished drug products, so clinical discussions with the prescriber about quality and bioequivalence expectations are appropriate. Cost tends to run 40-60% below the brand price.

Patients in rural Alaska, including communities accessible only by small aircraft or ferry, can receive USPS Priority Mail or FedEx Priority Overnight shipments of temperature-sensitive biologics provided appropriate cold-pack packaging is used.

Does Alaska Medicaid or Private Insurance Cover Vyleesi?

Alaska Medicaid does not cover bremelanotide as of January 2025. The state Medicaid formulary excludes drugs for sexual dysfunction that lack a demonstrated cost-effectiveness threshold under the Alaska Division of Health Care Services pharmacy benefit criteria 13.

Private insurance coverage varies. A 2021 analysis in the Journal of Sexual Medicine found that fewer than 20% of commercial health plans covered bremelanotide without significant prior-authorization barriers 14. Prior authorization for bremelanotide typically requires:

• A documented HSDD diagnosis using DSM-5 criteria
• Evidence that the low desire is not attributable to a relationship issue, another medical condition, or a medication side effect
• Trial and failure of at least one non-pharmacologic intervention (sex therapy, couples counseling) in some plans
• Confirmation of premenopausal status
• Attestation that flibanserin (Addyi) was trialed or is contraindicated, in some formularies

The prior-authorization process takes 5-15 business days on average. Denials can be appealed; the most effective appeal documentation includes a clinical letter from the prescriber citing the RECONNECT trial data 1 and the ACOG Committee Opinion on sexual dysfunction in women, which states that "HSDD is a real, distressing condition warranting treatment" 15.

Transferring an Existing Vyleesi Prescription to Alaska

A prescription written by a licensed provider in another U.S. state transfers to Alaska without reissue. Pharmacies in Alaska can fill a valid out-of-state prescription for bremelanotide because the drug is not a controlled substance. The receiving pharmacy simply needs the original prescriber's DEA and NPI numbers, the date written, and the quantity authorized.

If the original prescription was written more than 12 months ago, most pharmacies require a new prescription. Alaska telehealth services can issue a new prescription after a brief follow-up visit, typically 10-15 minutes, at which the provider confirms no change in blood-pressure status, medications, or reproductive health since the prior assessment.

Patients moving to Alaska from another state should contact their prior pharmacy and request a prescription transfer before relocating, or schedule a telehealth renewal visit within 30 days of arrival to avoid any gap in therapy.

Dosing, Administration, and What to Expect

Bremelanotide is injected subcutaneously in the abdomen or thigh 45 minutes before anticipated sexual activity. The maximum dose is 1.75 mg per 24 hours. There is no daily dosing regimen; the drug is strictly on-demand.

Nausea is the most reported adverse effect and occurred in 40% of participants in the RECONNECT trials versus 1% for placebo 1. Taking the injection at least 45 minutes before activity (rather than closer to 30 minutes) and lying down for 30-60 minutes afterward reduces nausea severity in most patients. The FDA label permits use of over-the-counter ondansetron or oral antiemetics if nausea is problematic 2.

Transient blood-pressure elevation peaks approximately 2 hours after injection and resolves within 12 hours for most patients. Women with a history of cardiovascular disease, uncontrolled hypertension, or those taking antihypertensive medications require closer monitoring. The RECONNECT open-label extension study followed patients for up to 52 weeks and found no cumulative cardiovascular signal beyond the known transient effect 1.

Flushing, hyperpigmentation of the face, gums, and breasts, and focal injection-site reactions occur in a minority of patients. Hyperpigmentation resolves after stopping the drug in most cases, though resolution may take several weeks.

Self-injection technique is covered during the telehealth visit and supplemented by the manufacturer's injection-training materials. Most patients are comfortable with self-injection within one practice session using the single-dose autoinjector design.

Clinical Evidence Supporting Bremelanotide Use

The RECONNECT program is the primary evidence base. Two Phase 3 randomized controlled trials published in Obstetrics and Gynecology (2019) enrolled 1,267 premenopausal women with DSM-5-confirmed HSDD across 68 clinical sites 1. Key findings:

• Mean increase in satisfying sexual events per month: 0.7 for bremelanotide vs. 0.4 for placebo (P<0.001)
• Clinically meaningful improvement on the FSDS-DAO item 13 ("distress about low sexual desire"): 49% of bremelanotide patients vs. 31% placebo
• Discontinuation due to adverse events: 8.8% bremelanotide vs. 1.7% placebo, driven primarily by nausea

A subsequent pharmacokinetic study in the Journal of Clinical Pharmacology (2020) confirmed that standard bremelanotide pharmacokinetics are unaffected by body weight up to 140 kg, supporting use across a wide patient population without dose adjustment 16.

The American College of Obstetricians and Gynecologists reaffirms in its sexual dysfunction guidance that pharmacologic treatment is appropriate for women who do not respond to psychosexual therapy alone 15. The International Society for Sexual Medicine guidelines similarly support bremelanotide as a second-line option after patient counseling on expected effect sizes 17.

Special Considerations for Alaska Patients

Altitude and cold-storage. Bremelanotide autoinjectors should be stored between 68°F and 77°F (20-25°C). Alaska homes in winter can drop below storage temperature if packages are left in unheated entryways or mailboxes. Patients should alert the pharmacy to ship with extended cold-pack protection and retrieve packages promptly.

Remote community access. For patients in communities without road access, USPS Priority Mail Express ships to every Alaska ZIP code, including bush communities. Some 503A pharmacies have experience with village delivery logistics and can coordinate with local health aides for cold-chain verification.

Alaska Native health systems. Women receiving care through the Alaska Native Tribal Health Consortium (ANTHC) or a tribal health organization may access Vyleesi through their existing prescriber relationship if that provider holds Alaska prescriptive authority. ANTHC-employed physicians and mid-levels can prescribe bremelanotide in the same manner as any Alaska-licensed provider.

Interaction with hormonal contraception. No pharmacokinetic interaction has been identified between bremelanotide and combined oral contraceptives, progestin-only pills, or IUDs in the published literature 2. Patients on hormonal contraception do not need to adjust their contraceptive regimen.

Prior flibanserin use. Flibanserin (Addyi), the once-daily oral HSDD medication approved in 2015, requires alcohol abstinence on days of use and carries a REMS program 18. Patients who discontinued flibanserin due to alcohol interaction or CNS side effects are reasonable candidates for bremelanotide. Insurance plans that require flibanserin trial first should receive prescriber documentation of that trial and its outcomes.